Scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
In Vitro Technologies Life Sciences division has a long history of supporting the Australian research community reaching back to 1958 and has developed a reputation for being one of the most dynamic and successful life science suppliers throughout Australia and New Zealand.
In Vitro Technologies are the premier supplier for cell biology and immunology research throughout Australia and New Zealand. Our range of cells, consumables, reagents, and laboratory equipment support your cell biology workflow in the fields of Cancer, Neuroscience, Immunology, Diabetes & Obesity, Cardiology, Pharmacology, and Drug Discovery. By partnering with world-class suppliers, In Vitro Technologies enables high quality, reproducible data, allowing researchers to accelerate discovery and publish high impact papers.
In Vitro Technologies would like to congratulate Dr. Andreas Behren and the Cancer Immunobiology team at the Olivia Newton-John Cancer Research (ONJCRI) Institute in Melbourne for winning the Advanced Cell Diagnostics $40,000 USD research grant.
In Vitro Technologies are proud to work closely with the new NSW Health Statewide Biobank, the largest biobank in the southern hemisphere.
In the latest vote of confidence that cellular immunotherapy is going to live up to its potential for transforming the way cancer is treated, this week Gilead Sciences purchased Kite Pharma, a leader in the development of chimeric antigen receptor (CAR) T cells, for $11.9 billion dollars.